Last reviewed · How we verify
Tenofovir gel
Tenofovir gel works by inhibiting the replication of HIV by blocking the action of reverse transcriptase.
Tenofovir gel works by inhibiting the replication of HIV by blocking the action of reverse transcriptase. Used for Prevention of HIV transmission in women.
At a glance
| Generic name | Tenofovir gel |
|---|---|
| Also known as | TFV, 9-(2-[Phosphonomethoxy]propyl)adenine, Tenofovir disoproxil, 9-[2-(Phosphonomethoxy)propyl]adenine, 9-[(R)-2-(phosphonomethoxy)propyl] adenine or PMPA |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | Nucleotide reverse transcriptase inhibitor |
| Target | Reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious disease |
| Phase | Phase 3 |
Mechanism of action
Tenofovir gel is a microbicide that contains the antiretroviral drug tenofovir, which is a nucleotide reverse transcriptase inhibitor (NtRTI). It is designed to be applied topically to the vagina to prevent HIV transmission. When applied, tenofovir is absorbed into the vaginal mucosa, where it inhibits the activity of reverse transcriptase, an enzyme that HIV uses to replicate its genetic material.
Approved indications
- Prevention of HIV transmission in women
Common side effects
- Vaginal irritation
- Vaginal discharge
- Vaginal itching
Key clinical trials
- A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP (PHASE2)
- Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding (PHASE4)
- Bone Mineral Density Substudy - An Ancillary Study to MTN-003
- Interventional Study of Mucosal and Antimicrobial Responses to Repeated Vaginal Applications of Tenofovir Gel in HIV Uninfected Women (PHASE1)
- Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults (NA)
- Safety and Acceptability of the Anti-Microbe Vaginal Gel, PMPA Gel (PHASE1)
- Evaluating the Safety of Tenofovir Vaginal Gel in HIV-Uninfected Pregnant Women (PHASE2)
- Safety and Acceptability of a Vaginal Microbicide (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tenofovir gel CI brief — competitive landscape report
- Tenofovir gel updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI